about
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayPrenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.Proteomic analysis of RCL2 paraffin-embedded tissues.Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in miceSignal transduction of somatostatin receptors negatively controlling cell proliferation.Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytesMelanoma-expressed CD70 is involved in invasion and metastasis.Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.Statins Reduce Melanoma Development and Metastasis through MICA Overexpression.KBA.62: a useful marker for primary and metastatic melanomas.The AF-1-deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumorsAn alternative fixative to formalin fixation for molecular applications: the RCL2(®)-CS100 approach.Stromal estrogen receptor-α promotes tumor growth by normalizing an increased angiogenesis.Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers.Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts.PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen.Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases.Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways.Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma.Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells.The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.High incidence of Epstein-Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large-cell lymphoma in children.Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma."Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies.Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.RREB1-MKL2 fusion in biphenotypic "oropharyngeal" sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer.
P50
Q24675853-AF084E37-D3C2-42DC-BDE7-E6A909AFD0C8Q24796687-19CC47E7-A2C5-4EFF-B9C5-7F5E3EDEA1C3Q33241448-3EBD1F25-20B6-4D6C-B0A5-1A37C1DD4309Q33384726-FFF64402-1D9B-413C-AE79-D3D7317858C9Q33530146-D9C4BCA9-5ECD-4D33-B727-54DF0265BBE8Q34000333-56908231-A8AA-40FC-AF2F-B1DCB606A508Q34012775-D0280E72-E5D7-43CB-85EB-B6168BC79DFFQ34087753-6D99647C-3A48-4E3F-BC24-15C7E7323751Q35199203-8A276F42-0B30-4D18-92E2-F997A189E386Q35847696-DE61B2F3-9B52-4A28-80B6-04C35D92F4E8Q36373347-600BDA85-F623-480F-9374-A6E6ACB95771Q36472971-EB5D5AB1-3174-432E-9ADE-D0CB9A4F5083Q36490331-1AEF08AB-D950-4F3B-A69C-41FF11DACCA6Q36678666-B143665E-AE62-4064-B189-78441A773E10Q37169883-E513CC1C-0DAF-4709-9DE7-E0B1AAA27202Q37481267-65D59147-5E40-4361-96B5-B33EEA84EFBEQ37849218-55C7898B-AF2B-43A6-92BB-D48A629E71E2Q39361038-0EBCCF51-F809-45EB-9CEC-0CC67DE58D32Q40012002-E40CC007-FB8D-4BBB-BC72-F4EC238B15FAQ40060097-44634B99-F017-4B8D-A655-219823F12F0AQ40610747-78A8CDCE-9EAA-46F6-A97E-59186AC0A89AQ40647683-A9B5597F-B9E3-4F08-AE07-C16392FB0B76Q40706382-EB810753-E48D-4966-90BD-48F3173D2BF9Q42013581-3D2AA3C7-8BDD-4200-9E4D-5310B74FC4C9Q42440259-DD291057-C9FC-4BDE-8C99-B0881CCA36A9Q42522118-95E0B835-33FE-4348-9B61-79ADB3B15BC5Q42802804-E56CBADB-0D16-47B7-BFEE-2066FD86DE21Q43963168-F5356F09-5D2E-4184-A1B1-B7A1B438D133Q44055118-1CE3A1D2-794B-491E-A1A7-15BA831C50EDQ44189310-A7AE57ED-589A-4091-B372-9731CD3229E8Q44693857-AAAFFB76-E481-4E24-9536-279FC7241058Q45774482-49BCB98D-C13C-4F50-A2CE-631BBD3707C1Q45936703-E85F0C39-7593-4076-9EC0-18B312ED0748Q45970694-53ABC123-B6DF-4AB3-8A53-2D15E371FD72Q46431136-1220C777-C9F0-45C7-9AC3-A3A2E6747B09Q46477657-6C1DD568-095F-49B8-B62B-138556E045BBQ47265758-2821DE7F-5391-465C-89D5-DE798C3BF81DQ47594502-1AA7DEB9-DD6E-4D65-AF51-82F5F8F1D962Q49605941-AA813FE7-BA21-4B4F-8994-02F852D5EEF5Q50859541-7E0C10FA-057F-4925-8E23-8FFFE34EA7C4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe Rochaix
@ast
Philippe Rochaix
@en
Philippe Rochaix
@es
Philippe Rochaix
@nl
Philippe Rochaix
@sl
type
label
Philippe Rochaix
@ast
Philippe Rochaix
@en
Philippe Rochaix
@es
Philippe Rochaix
@nl
Philippe Rochaix
@sl
prefLabel
Philippe Rochaix
@ast
Philippe Rochaix
@en
Philippe Rochaix
@es
Philippe Rochaix
@nl
Philippe Rochaix
@sl
P106
P31
P496
0000-0001-6238-1599